These are the 5 scientists and executives getting the richest off Moderna's spike to record highs

David L. Ryan/The Boston Globe/Getty ImagesScientist Xinhua Yan works in the lab at Moderna in Cambridge, MA on Feb. 28, 2020.
  • Moderna’s 30% gain in Monday trading is making a small group of scientists and executives a fortune.
  • The biotech company surged after announcing phase-one trials of its coronavirus vaccine successfully produced antibodies in all 45 participants.
  • Moderna now plans to finalise phase-three studies in July before bringing its vaccine to market in the fall.
  • Here are the five Moderna shareholders poised to make the most from its soaring stock price.
  • Watch Moderna trade live here.

Moderna stock soared to record highs on Monday, minting new fortunes for a small group of executives and scientists.

The biotech company’s shares launched as much as 30% higher on Monday after it revealed its coronavirus vaccine’s phase-one results. The experimental drug successfully produced antibodies in all 45 volunteers, Moderna said. The company plans to begin phase-three trials in July and to roll out a vaccine for emergency use in the fall.

The positive results lifted the market as well, with the S&P 500 leaping as much as 3.4% in Monday trading.

“We could not be happier with this interim data,” CEO Stephane Bancel said in a Monday call with analysts.

Some analysts think the stock still has room to run as its critical vaccine moves further into trials. Goldman Sachs lifted its Moderna price target to a Street-high $US105 from $US63 on Monday, saying “encouraging” phase-one results improve the drug’s likelihood of approval.

Here are the five Moderna shareholders set to win the most from the surging stock price, ranked in ascending order of shares owned. Shareholder data is sourced from Bloomberg.


Read more:
A Wall Street equity chief lays out 5 reasons why another ‘significant drawdown’ in stocks is coming right after the fastest crash in history


5. Lorence Kim

David L. Ryan/The Boston Globe via Getty ImagesModerna offices in Cambridge, Massachusetts.

Role: Chief financial officer

Shares held: 1,222,510


4. Stephen Hoge

Moderna/YouTube

Role: President

Shares held: 2,010,656


3. Timothy Springer

Screenshot from CanadaGairdnerAwards

Role: Early investor and Harvard Medical School professor

Shares held: 4,272,968


Read more:
GOLDMAN SACHS: Buy these 21 cheap, unappreciated stocks that offer above-average growth potential right now


2. Stephane Bancel

Andrew Harnik/AP ImagesModerna CEO Stephane Bancel attends a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House on March 2, 2020.

Role: Chief executive officer

Shares held: 7,348,167


1. Robert S. Langer

Barry Chin/The Boston Globe/Getty ImagesPortrait of Robert Langer in his Cape Cod residence in North Falmouth, MA on April 25, 2020.

Role: Academic co-founder and board member

Shares held: 11,509,357


Now read more markets coverage from Markets Insider and Business Insider:



Billionaire investor Howard Marks says ‘artificially supported’ markets will fall when the Fed’s aid slows



Moderna will spike another 25% from current levels after encouraging progress on coronavirus vaccine, Goldman says



Small companies are the biggest post-coronavirus battleground on Wall Street. 4 of the world’s best fund managers share their strategies for the space – and the single stocks they love.

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.